A citation-based method for searching scientific literature

Aleksey V Matveyenko, Sarah Dry, Heather I Cox, Artemis Moshtaghian, Tatyana Gurlo, Ryan Galasso, Alexandra E Butler, Peter C Butler. Diabetes 2009
Times Cited: 183







List of co-cited articles
847 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pancreatitis, pancreatic, and thyroid cancer with glucagon-like peptide-1-based therapies.
Michael Elashoff, Aleksey V Matveyenko, Belinda Gier, Robert Elashoff, Peter C Butler. Gastroenterology 2011
536
60



Biochemical and histological effects of exendin-4 (exenatide) on the rat pancreas.
J S Nachnani, D G Bulchandani, A Nookala, B Herndon, A Molteni, P Pandya, R Taylor, T Quinn, L Weide, L M Alba. Diabetologia 2010
139
42

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.
Sonal Singh, Hsien-Yen Chang, Thomas M Richards, Jonathan P Weiner, Jeanne M Clark, Jodi B Segal. JAMA Intern Med 2013
255
38


The human GLP-1 analog liraglutide and the pancreas: evidence for the absence of structural pancreatic changes in three species.
Niels C B Nyborg, Anne-Marie Mølck, Lars W Madsen, Lotte Bjerre Knudsen. Diabetes 2012
103
28


Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus.
Benjamin M Scirica, Deepak L Bhatt, Eugene Braunwald, P Gabriel Steg, Jaime Davidson, Boaz Hirshberg, Peter Ohman, Robert Frederich, Stephen D Wiviott, Elaine B Hoffman,[...]. N Engl J Med 2013
25

A critical analysis of the clinical use of incretin-based therapies: Are the GLP-1 therapies safe?
Peter C Butler, Michael Elashoff, Robert Elashoff, Edwin A M Gale. Diabetes Care 2013
192
24

Alogliptin after acute coronary syndrome in patients with type 2 diabetes.
William B White, Christopher P Cannon, Simon R Heller, Steven E Nissen, Richard M Bergenstal, George L Bakris, Alfonso T Perez, Penny R Fleck, Cyrus R Mehta, Stuart Kupfer,[...]. N Engl J Med 2013
24

Exenatide does not evoke pancreatitis and attenuates chemically induced pancreatitis in normal and diabetic rodents.
Krystyna Tatarkiewicz, Pamela A Smith, Emmanuel J Sablan, Clara J Polizzi, Donald E Aumann, Christiane Villescaz, Diane M Hargrove, Bronislava R Gedulin, Melissa G W Lu, Lisa Adams,[...]. Am J Physiol Endocrinol Metab 2010
77
29


Pancreatic safety of incretin-based drugs--FDA and EMA assessment.
Amy G Egan, Eberhard Blind, Kristina Dunder, Pieter A de Graeff, B Timothy Hummer, Todd Bourcier, Curtis Rosebraugh. N Engl J Med 2014
316
23

The effects of 13 wk of liraglutide treatment on endocrine and exocrine pancreas in male and female ZDF rats: a quantitative and qualitative analysis revealing no evidence of drug-induced pancreatitis.
Niels Vrang, Jacob Jelsing, Lotte Simonsen, Andres Eskjær Jensen, Inger Thorup, Henrik Søeborg, Lotte Bjerre Knudsen. Am J Physiol Endocrinol Metab 2012
65
33

A cohort study of acute pancreatitis in relation to exenatide use.
D D Dore, G L Bloomgren, M Wenten, C Hoffman, C R Clifford, S G Quinn, D K Braun, R A Noel, J D Seeger. Diabetes Obes Metab 2011
114
21


Relative risk of acute pancreatitis in initiators of exenatide twice daily compared with other anti-diabetic medication: a follow-up study.
M Wenten, J A Gaebler, M Hussein, E M Pelletier, D B Smith, P Girase, R A Noel, D K Braun, G L Bloomgren. Diabet Med 2012
66
25

Reanalysis of study of pancreatic effects of incretin therapy: methodological deficiencies.
S Bonner-Weir, P A In't Veld, G C Weir. Diabetes Obes Metab 2014
43
37

Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies.
Ling Li, Jiantong Shen, Malgorzata M Bala, Jason W Busse, Shanil Ebrahim, Per Olav Vandvik, Lorena P Rios, German Malaga, Evelyn Wong, Zahra Sohani,[...]. BMJ 2014
140
16

No evidence of drug-induced pancreatitis in rats treated with exenatide for 13 weeks.
K Tatarkiewicz, P Belanger, G Gu, D Parkes, D Roy. Diabetes Obes Metab 2013
40
37

Exenatide therapy and the risk of pancreatitis and pancreatic cancer in a privately insured population.
John A Romley, Dana P Goldman, Matthew Solomon, Daniel McFadden, Anne L Peters. Diabetes Technol Ther 2012
62
24

Sitagliptin: review of preclinical and clinical data regarding incidence of pancreatitis.
S S Engel, D E Williams-Herman, G T Golm, R J Clay, S V Machotka, K D Kaufman, B J Goldstein. Int J Clin Pract 2010
112
14

Exenatide (exendin-4)-induced pancreatitis: a case report.
Paul S Denker, Paul E Dimarco. Diabetes Care 2006
104
13

Glucagon-like Peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation.
Lotte Bjerre Knudsen, Lars Wichmann Madsen, Søren Andersen, Kasper Almholt, Anne S de Boer, Daniel J Drucker, Carsten Gotfredsen, Frederikke Lihme Egerod, Anne Charlotte Hegelund, Helene Jacobsen,[...]. Endocrinology 2010
338
13


One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice.
Kathryn Aston-Mourney, Shoba L Subramanian, Sakeneh Zraika, Thanya Samarasekera, Daniel T Meier, Lynn C Goldstein, Rebecca L Hull. Am J Physiol Endocrinol Metab 2013
29
44




The biology of incretin hormones.
Daniel J Drucker. Cell Metab 2006
11

Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes.
Alexandra E Butler, Juliette Janson, Susan Bonner-Weir, Robert Ritzel, Robert A Rizza, Peter C Butler. Diabetes 2003
11

Incretin therapies and risk of hospital admission for acute pancreatitis in an unselected population of European patients with type 2 diabetes: a case-control study.
Carlo B Giorda, Roberta Picariello, Elisa Nada, Barbara Tartaglino, Lisa Marafetti, Giuseppe Costa, Roberto Gnavi. Lancet Diabetes Endocrinol 2014
33
33


Risk of pancreatitis in patients treated with incretin-based therapies.
Juris J Meier, Michael A Nauck. Diabetologia 2014
67
16

Incretin based drugs and risk of acute pancreatitis in patients with type 2 diabetes: cohort study.
Jean-Luc Faillie, Laurent Azoulay, Valerie Patenaude, Dominique Hillaire-Buys, Samy Suissa. BMJ 2014
56
19

Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
Steven P Marso, Gilbert H Daniels, Kirstine Brown-Frandsen, Peter Kristensen, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Lasse S Ravn,[...]. N Engl J Med 2016
11

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial.
Alan Garber, Robert Henry, Robert Ratner, Pedro A Garcia-Hernandez, Hiromi Rodriguez-Pattzi, Israel Olvera-Alvarez, Paula M Hale, Milan Zdravkovic, Bruce Bode. Lancet 2009
765
10

Exenatide and rare adverse events.
Syed R Ahmad, Joslyn Swann. N Engl J Med 2008
92
10

An analysis of characteristics of subjects examined for incretin effects on pancreatic pathology.
Evis Harja, Jonathan Lord, Jay S Skyler. Diabetes Technol Ther 2013
22
45

Case report of acute necrotizing pancreatitis associated with combination treatment of sitagliptin and exenatide.
Shridhar N Iyer, Almond J Drake, R Lee West, Carlos E Mendez, Robert J Tanenberg. Endocr Pract 2012
32
31

The human GLP-1 analogs liraglutide and semaglutide: absence of histopathological effects on the pancreas in nonhuman primates.
Carsten F Gotfredsen, Anne-Marie Mølck, Inger Thorup, Niels C Berg Nyborg, Zaki Salanti, Lotte Bjerre Knudsen, Marianne O Larsen. Diabetes 2014
40
25

Acute pancreatitis in association with type 2 diabetes and antidiabetic drugs: a population-based cohort study.
Antonio Gonzalez-Perez, Raymond G Schlienger, Luis A García Rodríguez. Diabetes Care 2010
91
9

Safety of dipeptidyl peptidase-4 inhibitors: a meta-analysis of randomized clinical trials.
Matteo Monami, Ilaria Dicembrini, Daniele Martelli, Edoardo Mannucci. Curr Med Res Opin 2011
155
9


A meta-analysis of serious adverse events reported with exenatide and liraglutide: acute pancreatitis and cancer.
Carlos Alves, Francisco Batel-Marques, Ana F Macedo. Diabetes Res Clin Pract 2012
102
9

Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.
Samuel S Engel, Elizabeth Round, Gregory T Golm, Keith D Kaufman, Barry J Goldstein. Diabetes Ther 2013
88
10

Pharmacology, physiology, and mechanisms of incretin hormone action.
Jonathan E Campbell, Daniel J Drucker. Cell Metab 2013
731
9

Occurrence of spontaneous pancreatic lesions in normal and diabetic rats: a potential confounding factor in the nonclinical assessment of GLP-1-based therapies.
Kristina D Chadwick, Anthony M Fletcher, M Cecilia Parrula, Susan Bonner-Weir, Raja S Mangipudy, Evan Janovitz, Michael J Graziano, Denis Roy, Timothy P Reilly. Diabetes 2014
23
39

Pancreatitis associated with the use of GLP-1 analogs and DPP-4 inhibitors: a case/non-case study from the French Pharmacovigilance Database.
Jean-Luc Faillie, Samy Babai, Sabrina Crépin, Virginie Bres, Marie-Laure Laroche, Hervé Le Louet, Pierre Petit, Jean-Louis Montastruc, Dominique Hillaire-Buys. Acta Diabetol 2014
51
17


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.